What Is Cuvitru?

Cuvitru (generic name: immune globulin) is derived from human plasma, and it is given to patients with antibody deficiencies to protect against infections.

This medicine belongs to the immune globulins drug class. Cuvitru is FDA approved to be used as a monotherapy or adjunct therapy with other medications.

Cuvitru Treatment/Therapy

Cuvitru is an immunoglobulin solution that is administered via subcutaneous infusion only.  It works by replacing antibodies that are not functioning properly or not present in the human body to help fight off infections. FDA-approved doses are given to increase extremely low blood immunoglobulin levels to required levels.

Cuvitru Dosing

Cuvitru is administered under the skin (subcutaneously), typically by a trained healthcare professional.

Dosing varies from patient to patient.

Factors That Influence Dosing Calculations:

• Body weight
• Blood IgG levels
• Medical history
• Current conditions
• Clinical response to the treatment

Based on these factors, the patient (a child or adult) may be prescribed a loading dose of at least 1.0-2.5 ml/kg of body weight divided over a few consecutive days.

Following this loading dose, patients will start to receive Cuvitru at regular intervals from daily to once every two weeks.

The total monthly dose will be between 1.5-5.0 ml/kg of body weight after the loading dose. 

The doctor may adjust the dose over time to achieve the desired clinical response and serum IgG levels.

For patients who are switching from another IVIG brand, the Cuvitru dose will be based on the previous IVIG dose and will be adjusted according to the number and frequency of infusion.

It is not recommended to make changes to the dose or dosing interval without talking to the doctor.

If you miss a dose, it is important to speak to the doctor as early as possible and get a new dosing schedule. Avoid doubling the dose to catch up.